Also trades as: NOVN.SW (SIX) · $vol 405M · NVS (NYSE) · $vol 285M · NVS.TO (TSX) · $vol 0M

$134.20

-6.73 (-4.78%)

Weekly Expected Move ±9.8%

$108 $121 $134 $147 $160

OTC · Healthcare · Drug Manufacturers - General · Tech Score Sell · Power 43 · $255.1B mcap · 1.61B float · 0.0010% daily turnover · Short 8% of daily vol

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions Dark Pool Short Interest

Income Trends

Revenue

$57.1B +10.4% ▲

5Y CAGR: +2.7%

Gross Profit

$42.9B +10.2% ▲

5Y CAGR: +4.3%

Operating Income

$17.8B +22.4% ▲

5Y CAGR: +11.9%

Net Income

$14.6B +22.7% ▲

5Y CAGR: +12.7%

EPS (Diluted)

$7.49 +27.6% ▲

5Y CAGR: +15.0%

EBITDA

$24.0B +15.7% ▲

5Y CAGR: +9.0%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$52.9B	$51.8B	$46.7B	$51.7B	$57.1B
YoY Growth	+6.0%	-2.0%	-10.0%	+10.8%	+10.4%
Cost of Revenue	$15.9B	$15.5B	$12.0B	$12.8B	$14.3B
Gross Profit	$37.0B	$36.3B	$34.6B	$38.9B	$42.9B
Gross Margin	70.0%	70.1%	74.2%	75.2%	75.0%
R&D Expenses	$9.5B	$10.0B	$11.4B	$10.0B	$11.2B
SG&A Expenses	$14.9B	$14.3B	$12.5B	$12.6B	$13.9B
Operating Expenses	$25.3B	$27.1B	$24.9B	$24.4B	$25.1B
Operating Income	$11.7B	$9.2B	$9.8B	$14.5B	$17.8B
Operating Margin	22.1%	17.7%	20.9%	28.1%	31.2%
Interest Expense	$907M	$860M	$855M	$1.0B	$1.2B
Income Before Tax	$25.0B	$8.4B	$9.1B	$13.6B	$17.1B
Tax Expense	$2.1B	$1.4B	$551M	$1.7B	$2.5B
Net Income	$24.0B	$7.0B	$14.8B	$11.9B	$14.6B
Net Margin	45.4%	13.4%	31.8%	23.1%	25.6%
EPS (Diluted)	$10.65	$3.27	$7.58	$5.87	$7.49
EBITDA	$17.2B	$15.2B	$19.5B	$20.7B	$24.0B
Shares Outstanding	2.26B	2.20B	2.09B	2.04B	1.96B

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$13.2B	$13.6B	$13.6B	$14.8B	$14.4B	$13.4B	$12.9B	$14.1B
Cost of Revenue	$3.2B	$3.3B	$3.2B	$3.3B	$3.5B	$3.6B	$3.4B	$3.6B
Gross Profit	$9.9B	$10.2B	$10.4B	$11.5B	$10.8B	$9.9B	$9.5B	$10.5B
Gross Margin	75.4%	75.5%	76.3%	77.6%	75.4%	73.4%	73.8%	74.5%
R&D Expenses	$2.4B	$2.8B	$2.4B	$2.7B	$2.9B	$2.9B	$2.7B	$2.7B
SG&A Expenses	$3.1B	$3.5B	$3.1B	$3.4B	$3.3B	$3.5B	$3.1B	$3.2B
Operating Expenses	$6.3B	$6.7B	$5.7B	$6.7B	$6.3B	$6.3B	$5.8B	$5.9B
Operating Income	$3.6B	$3.5B	$4.7B	$4.9B	$4.5B	$3.8B	$3.7B	$4.6B
Operating Margin	27.5%	26.0%	34.2%	32.8%	31.3%	28.1%	28.5%	32.8%
Interest Expense	$264M	$275M	$274M	$301M	$281M	$306M	$336M	$452M
Income Before Tax	$3.4B	$3.3B	$4.5B	$4.5B	$4.2B	$3.9B	$3.8B	$4.2B
Tax Expense	$200M	$465M	$810M	$507M	$266M	$821M	$670M	$990M
Net Income	$3.2B	$2.8B	$3.7B	$4.0B	$3.9B	$2.4B	$3.1B	$3.2B
Net Margin	24.2%	20.8%	26.9%	27.2%	27.4%	18.1%	24.1%	22.7%
EPS (Diluted)	$1.57	$1.41	$1.82	$2.06	$2.00	$1.26	$1.62	$1.67
EBITDA	$5.6B	$5.2B	$5.8B	$6.1B	$5.8B	$6.2B	$4.8B	$5.8B
Shares Outstanding	2.03B	2.00B	1.98B	1.96B	1.96B	1.93B	1.92B	1.91B

NVSEF OTC

Income Trends

Profit Margins

Year-over-Year Growth

Sign in to InsiderStreet